Press Release

RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO

6 years ago May 01, 2018

A revised binding term sheet reflects improved terms and positions the parties for closing the...

RepliCel CEO Provides 2018 Shareholder Update

6 years ago Jan 24, 2018

With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for...

RepliCel Life Sciences Lands Commitment for Key Investment Partnership

6 years ago Jan 15, 2018

YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater...

RepliCel Life Sciences Successfully Closes Financing

6 years ago Oct 18, 2017

Shareholders commit to non-brokered private placement in clear support of the Company’s partnership strategy VANCOUVER,...

RepliCel’s Partnership Initiatives Mature into Licensing Negotiations

7 years ago Sep 12, 2017

Due diligence and confidential discussions now moving into negotiations for products in both the tendon...

RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

7 years ago Sep 06, 2017

Delivery of RepliCel’s patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization scheduleVANCOUVER,...

RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program

7 years ago Aug 15, 2017

Regenerative Medicine Company to Adopt ThawSTAR® Cell Thawing Systems to De-Risk Cell Therapy Clinical TrialVANCOUVER,...

Prominent Skin Aging Researcher Provides Insights into RepliCel’s Clinical Data

7 years ago Aug 09, 2017

“We believe that this novel therapy has the potential to rejuvenate skin in a way...

RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map

7 years ago Jun 12, 2017

Data from this project expected to take RepliCel’s products to next level of potential commercial...

RepliCel CEO Provides Company Outlook

7 years ago May 24, 2017

A data-rich 2017 positions RepliCel for maturity through the next phase of its product development,...

United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies

7 years ago Apr 24, 2017

With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to...

Positive Results from RepliCel’s RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date

7 years ago Apr 03, 2017

Interim trial results lead researchers to conclude that the injection of RCS-01 is not only...

RepliCel’s Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems

7 years ago Mar 27, 2017

First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration...

RepliCel’s Phase 1 Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints

7 years ago Mar 13, 2017

Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategyVANCOUVER,...

RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization

7 years ago Mar 06, 2017

VANCOUVER, BC – March 7, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”...

RepliCel Life Sciences Announces Re-pricing of Warrants

7 years ago Mar 05, 2017

VANCOUVER, BC – March 6, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...

RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector

7 years ago Feb 27, 2017

VANCOUVER, BC – February 28, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”...

RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement

7 years ago Feb 23, 2017

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

RepliCel Announces European Patents for its Innovative Dermal Injector Technologies

7 years ago Feb 08, 2017

RCI-02, RepliCel’s nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin injections...

Replicel Life Sciences Inc. Announces Brokered Private Placement

7 years ago Feb 06, 2017

VANCOUVER, BC – February 7, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...

by Type

by Topic

by month

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.